MEI Pharma Inc. said its ME-401 drug showed anticancer activity in patients with different types of lymphoma in a phase 1b study, according to data presented at the 2018 American Society of Clinical Oncology meeting.
The study showed that 90% of the 30 evaluable patients with follicular lymphoma whose disease returned or did not respond to treatments, chronic lymphocytic lymphoma, or small lymphocytic lymphoma saw a reduction in their disease.
The San Diego-based company intends to conduct another study of the drug later in 2018.
The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on-site and an additional 3,350 abstracts to be published online.
